Novavax, Inc. (NVAX)
| Market Cap | 997.23M |
| Revenue (ttm) | 682.16M |
| Net Income (ttm) | -187.50M |
| Shares Out | 160.84M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | 58.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,814,796 |
| Open | 6.30 |
| Previous Close | 6.39 |
| Day's Range | 6.09 - 6.38 |
| 52-Week Range | 3.81 - 23.86 |
| Beta | 3.14 |
| Analysts | Buy |
| Price Target | 17.83 (+187.58%) |
| Earnings Date | May 9, 2025 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $17.83, which is an increase of 187.58% from the latest price.
News
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine Ful...
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CB...
The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.
The agency is sitting on a decision to grant full approval for Novavax's shot.
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the m...
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...
Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX) Leerink Partners 2025 Global Healthcare Conference March 11, 2025 12:00 AM ET Company Participants John Jacobs - CEO Ruxandra Draghia - Head of R&D Jim Kelly - CFO Confere...
Novavax Announces Changes to Board of Directors
James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md. , March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasd...
Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX) TD Cowen 45th Annual Health Care Conference March 4, 2025 9:10 AM ET Company Participants John Jacobs - President and Chief Executive Officer Ruxandra Draghia - Executive ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc.'s Q4 2024 earnings — released yesterday — show a significant revenue decline and continued losses, despite cost-cutting measures and the deal with Sanofi, worth up to $1.2bn. The company...
Novavax to Participate in Upcoming March Investor Conferences
GAITHERSBURG, Md. , Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45 th...
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Execut...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sale...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.
Novavax Stock Is Rising. Revenue Beat Estimates.
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines.
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 mi...
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
GAITHERSBURG, Md. , Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth...
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vot...
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax...
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , ...
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.